Revolution Medicines, Inc. reiterated earnings guidance for the full year 2024. The company is reiterating its projected full year 2024 GAAP net loss to be between $480 million and $520 million, which includes estimated non-cash stock-based compensation expense of between $70 million and $80 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
40 USD | -0.42% | +5.70% | +39.68% |
May. 09 | Wedbush Raises Price Target on Revolution Medicines to $46 From $42, Maintains Outperform Rating | MT |
May. 08 | Revolution Medicines Q1 Net Loss Narrows | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+39.68% | 6.63B | |
+45.53% | 56.65B | |
-7.28% | 39.44B | |
+39.19% | 39.03B | |
-6.65% | 26.86B | |
+12.25% | 26.75B | |
-21.47% | 19.03B | |
+0.71% | 12.28B | |
+23.85% | 12.26B | |
+27.01% | 12.04B |
- Stock Market
- Equities
- RVMD Stock
- News Revolution Medicines, Inc.
- Revolution Medicines, Inc. Reiterates Earnings Guidance for the Full Year 2024